Business context and reporting period
Inogen, Inc. filed this Form 10-K for the fiscal year ended December 31, 2020. It is an annual report, not a standalone quarterly filing; Q4 figures below are the reported quarter ended December 31. Inogen develops, manufactures, and sells or rents portable oxygen concentrators and related respiratory products, including the Tidal Assist Ventilator (TAV). COVID-19 and related public-health measures materially affected demand and operations during 2020.
Financial performance and liquidity
| Metric | FY 2020 | FY 2019 |
|---|---|---|
| Total revenue | $308.5 million | $361.9 million |
| Sales revenue | $280.2 million | $340.5 million |
| Rental revenue | $28.3 million | $21.4 million |
| Gross profit / gross margin | $138.2 million / 44.8% | $171.9 million / 47.5% |
| Operating income (loss) | $(12.0) million | $19.8 million |
| Net income (loss) | $(5.8) million | $21.0 million |
| Operating cash flow | $37.0 million | $40.6 million |
| Adjusted EBITDA (non-GAAP) | $21.6 million | $43.3 million |
Sales gross margin fell to 44.1% from 48.3%, which management attributed to lower average selling prices, a greater share of lower-margin business-to-business sales, and higher unit costs and manufacturing inefficiencies. Rental gross margin increased to 52.1% from 34.1%, supported by reimbursement rates, a higher proportion of billable patients, and lower rental servicing and depreciation costs.
Q4 2020 revenue was $74.0 million, versus $78.9 million in Q4 2019. Q4 gross profit was $34.1 million versus $33.9 million; net loss was $5.1 million versus $1.4 million, and diluted loss per share was $0.23 versus $0.06.
At year-end, cash and cash equivalents were $212.0 million and marketable securities were $19.3 million; net working capital was $249.0 million. The filing reports no borrowings; liabilities included a $26.9 million earnout liability and $10.0 million of operating lease liabilities. Investing cash outflow was $25.6 million, including $17.6 million for rental equipment, property and equipment, and intangible assets. Management said existing resources and expected cash generation should meet operating and investing needs for at least 12 months.
Material changes versus prior comparable period
- Revenue declined 14.8% year over year. Sales revenue fell 17.7%, while rental revenue grew 32.3%.
- Systems sold declined to approximately 178,900 from 201,100. Direct-to-consumer domestic sales fell 22.1%; domestic and international business-to-business sales fell 9.4% and 20.3%, respectively.
- Management linked weaker sales to COVID-19 effects on travel, consumer confidence, physician interactions, HME purchasing, and international tenders, as well as early-2020 G5 component constraints.
- Net loss replaced prior-year net income. Lower gross profit and higher acquired-intangible amortization outweighed reduced sales and marketing expense and COVID-related relief income.
- Rental patients increased to approximately 32,200 from 25,300; capped patients as a share of patients on service declined to 11.7% from 20.3%.
Outlook, management commentary, risks and unusual items
The filing provides no numerical revenue or earnings guidance. Management planned to resume selective sales hiring in 2021, with limited additions in the first half while COVID-19 effects continued; it also planned to increase marketing from 2020 levels, though below a typical year, expand rental intake and pursue a pricing trial. Management expected TAV to make only a limited revenue contribution in 2021 and anticipated increased R&D expense, including acquired-intangible amortization. Entry into China was a possibility as early as late 2021, subject to regulatory and other delays.
- COVID-19 and reimbursement: The pandemic disrupted sales, referrals, travel and tenders. Temporary Medicare rate and administrative relief supported rentals, but its duration was uncertain. CMS did not award oxygen contracts in the 2021 competitive-bidding round; future reimbursement rules could change after the public-health emergency.
- TAV coding and adoption: CMS reversed the product’s initially confirmed HCPCS coding, and Inogen sued CMS officials and Palmetto GBA in 2020. Unresolved reimbursement classification could constrain sales and rentals.
- Customer and supply concentration: One customer exceeded 10% of 2020 revenue, and a small group of suppliers accounted for a significant portion of component purchases. The company cited single-source supply exposure and prior G5 component delays.
- Legal matters: Inogen recorded an $8.0 million liability for a Breathe Technologies dispute settled in January 2021; the filing also disclosed a pending securities class action and stayed derivative suits.
- CARES Act support: Inogen received $6.2 million in Provider Relief Fund support, recognizing $5.3 million in other income and $0.9 million as a benefit to general and administrative expense.
- Management change: Nabil Shabshab became CEO and president in February 2021, succeeding Scott Wilkinson.
- Controls and audit: Management and Deloitte reported effective internal control over financial reporting; Deloitte issued unqualified opinions on the financial statements and internal controls. The auditor identified lifetime-warranty revenue deferral estimates as a critical audit matter.
Important facts for investors to verify
- Whether revenue, unit sales and margins recover, and whether rental growth can offset continued weakness in equipment sales.
- The persistence of Medicare reimbursement relief and the final post-emergency payment rules, including potential effects on rental economics.
- The outcome of the TAV coding lawsuit and whether the product achieves workable reimbursement and commercial adoption.
- Customer concentration, supplier continuity, and the company’s ability to avoid further manufacturing constraints.
- The settlement’s final cash and escrow effects, and the status and potential costs of the securities and derivative litigation.
- Cash-flow and liquidity performance against planned facility leases, rental-equipment investment, and the reported $60.2 million of purchase obligations due within one year.